Adello Revenue and Competitors

Redwood City,

Location

N/A

Total Funding

Marketing

Industry

Estimated Revenue & Valuation

  • Adello's estimated annual revenue is currently $2.7M per year.(i)
  • Adello's estimated revenue per employee is $150,000

Employee Data

  • Adello has 18 Employees.(i)
  • Adello grew their employee count by -10% last year.

Adello's People

NameTitleEmail/Phone
1
FounderReveal Email/Phone
2
VP Engineering Reveal Email/Phone
3
HEAD OF OPERATIONSReveal Email/Phone
4
COUNTRY MANAGER Country Manager Switzerland Reveal Email/Phone
5
Head Finance Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$31M124-17%N/AN/A
#2
$48.1M17523%N/AN/A
#3
$10M5016%N/AN/A
#4
$5.7M3015%N/AN/A
#5
$7.2M366%N/AN/A
#6
$8.6M4334%N/AN/A
#7
$22.8M91-12%N/AN/A
#8
$4.9M28-59%N/AN/A
#9
$21.5M86-4%N/AN/A
#10
$40.7M1486%N/AN/A
Add Company

What Is Adello?

Adello is the leading Swiss AdTech provider. We leverage our award-winning deep learning technology and self-improving campaigns to deliver exceptional accuracy in audience targeting for every campaign. Our patented AI improves mobile advertising campaigns automatically in real-time and ensures Brand Safety. We serve hundreds of blue-chip clients on three continents, such as L'Oreal, Sony Music, Samsung, BMW, Warner Bros, UBS, and Ikea. Their trust is important to us. That's why now, during the Covid19 crisis, we support advertisers with additional services and creative consultations to achieve their brand and direct-response goals. Adello's proprietary technology has won multiple awards, including Venture Leader China (2015), Technavio Global Top 16 Big Data Companies (2014), Gartner's Cool Vendor in Infrastructure (2012), Top100 Startup Winner (2012 & 2013) and CRN Big Data 100 (2012). For more information, please visit www.adello.com or contact us directly at info@adello.com.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$2.7M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Adello News

2022-04-17 - Oncology Biosimilars Enter an Era of Expansion

the same indications, Amgen's filgrastim (Neupogen) also has 2 products pending approval: Filgrastim Kashiv (Adello Biologics/AE...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M18-57%N/A
#2
$2.1M180%N/A
#3
$1.6M186%N/A
#4
$1.6M186%N/A
#5
$1.5M19N/AN/A